Response to Raschi E et al. 'Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction'

被引：2

|

作者：

Gupta, M. A. ^{[1
]}

Vujcic, B. ^{[1
]}

Gupta, A. K. ^{[2
]}

机构：

[1] Univ Western Ontario, Schulich Sch Med & Dent, Dept Psychiat, London, ON, Canada

[2] Univ Toronto, Dept Med, Fac Med, Toronto, ON, Canada

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2020年 / 34卷 / 08期

关键词：

D O I：

10.1111/jdv.16378

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

收藏

页码：E431 / E432

页数：2

相关论文

共 4 条

[1] Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction
Raschi, E.
Salvo, F.
La Placa, M.
Poluzzi, E.
De Ponti, F.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (08) : E430 - E431
[2] Author's Reply to Pestana et al. Comment on: "Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?"
Alavi, Afsaneh
Raffals, Laura
[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (04) : 593 - 594
[3] Author’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”
Afsaneh Alavi
Laura Raffals
[J]. American Journal of Clinical Dermatology, 2022, 23 : 593 - 594
[4] Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from theUS FDAAdverse Events Reporting System pharmacovigilance database
Gupta, M. A.
Vujcic, B.
Sheridan, A. D.
Gupta, A. K.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (07) : 1564 - 1568